regadenoson has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dugan, E; Jaber, WA; Parizher, G | 1 |
| Hernandez, LE | 1 |
| Auerbach, A; Chan, N; Delphin, J; Kataria, V; Makaryus, JN | 1 |
| Abraham, MR; Abraham, TP; Bengel, FM; Bravo, PE; Merrill, J; Pinheiro, A; Pozios, I; Tsui, BM; Wahl, RL | 1 |
4 other study(ies) available for regadenoson and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
What is this image? 2023 image 2 results: In vivo demonstration of regadenoson-induced severe ischemia on PET myocardial perfusion imaging in a patient with hypertrophic obstructive cardiomyopathy and nonobstructive coronary artery disease.
Topics: Cardiomyopathy, Hypertrophic; Coronary Artery Disease; Humans; Ischemia; Myocardial Perfusion Imaging | 2023 |
Myocardial stress perfusion magnetic resonance in children with hypertrophic cardiomyopathy.
Topics: Adolescent; Cardiomyopathy, Hypertrophic; Child; Contrast Media; Female; Gadolinium; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Myocardium; Organometallic Compounds; Purines; Pyrazoles; Stroke Volume; Young Adult | 2018 |
Marked multi-distribution myocardial ischemia in a patient with hypertrophic cardiomyopathy and no obstructive coronary artery disease.
Topics: Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Coronary Artery Disease; Electrocardiography; Female; Humans; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Purines; Pyrazoles; Systole; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2020 |
Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy.
Topics: Adenosine A2 Receptor Antagonists; Cardiomyopathy, Hypertrophic; Coronary Circulation; Dipyridamole; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Positron-Emission Tomography; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; ROC Curve; Severity of Illness Index; Stroke Volume; Vasodilator Agents | 2012 |